$ cat ./records/r21-matrix-m-malaria-vaccine-receives-first-national-regulatory-a-2023.txt
R21/Matrix-M malaria vaccine receives first national regulatory approval — in Ghana
[RECORD.TXT] · cat --full
Ghana's Food and Drugs Authority became the first national regulator in the world to grant full licensure to the R21/Matrix-M malaria vaccine — developed by the University of Oxford with Gates Foundation funding, and manufactured by the Serum Institute of India. With 75–77% efficacy in trials — higher than RTS,S — R21 met the WHO's own target for malaria vaccine performance. The Serum Institute aimed to produce up to 200 million doses annually, dramatically exceeding the manufacturing capacity available for RTS,S, positioning R21 as the higher-volume vaccine for sub-Saharan Africa's mass vaccination programmes.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
WHO grants prequalification to R21/Matrix-M — the second malaria vaccine to achieve global procurement status
Next →
Gates Foundation Invests $40 Million to Accelerate mRNA Vaccine Manufacturing in Africa
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.